ReviewThe oncologist2013
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.
Review in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Identification of prognostic signatures in pheochromocytomas and paragangliomas based on mitochondrial autophagy and ferroptosis in TCGA and GEO datasets.Discover oncology · 2026Article
- Perioperative Management Challenges in Silent Pheochromocytoma: A Case Report and Literature Review.Clinical case reports · 2025Article
- Personalized oncology in pheochromocytomas and paragangliomas: integrating genetic analysis with machine learning.Medical oncology (Northwood, London, England) · 2024Article
- From diagnosis to resistance: a symphony of miRNAs in pheochromocytoma progression and treatment response.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis.European journal of endocrinology · 2022Review
- Metastatic Pheochromocytoma Diagnosed withWorld journal of nuclear medicine · 2022Article
- Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.Nanotheranostics · 2022Review
- Pheochromocytoma as a cause of repeated acute myocardial infarctions, heart failure, and transient erythrocytosis: A case report and review of the literature.World journal of clinical cases · 2021Article
- Bioinformatic screening and identification of downregulated hub genes in adrenocortical carcinoma.Experimental and therapeutic medicine · 2020Article
- Comprehensive Analysis of Aberrantly Expressed Competitive Endogenous RNA Network and Identification of Prognostic Biomarkers in Pheochromocytoma and Paraganglioma.OncoTargets and therapy · 2020Article
- Review
- Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.Endocrine pathology · 2018Article
- Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing's syndrome in patients with bilateral adrenal disease.Langenbeck's archives of surgery · 2017Article
- NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.OncoTargets and therapy · 2017Article
- Peptide receptor radionuclide therapy for metastatic paragangliomas.Medical oncology (Northwood, London, England) · 2016Article
- Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Patient with inoperable pheochromocytoma.Current oncology (Toronto, Ont.) · 2015Article
- MicroRNAs used as novel biomarkers for detecting cancer metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Multiple nodal locoregional recurrence of pheochromocytoma.International journal of surgery case reports · 2015Article
- Incidentally detected inoperable malignant pheochromocytoma with hepatic metastasis treated by transcatheter arterial chemoembolization.Endocrinology and metabolism (Seoul, Korea) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare catecholamine-secreting tumors derived from chromaffin cells originating in the neural crest. These tumors represent a significant diagnostic and therapeutic challenge because the diagnosis of malignancy is frequently made in retrospect by the development of metastatic or recurrent disease. Complete surgical resection offers the only potential for cure; however, recurrence can occur even after apparently successful resection of the primary tumor. The prognosis for malignant disease is poor because traditional treatment modalities have been limited. The last decade has witnessed exciting discoveries in the study of PCCs and PGLs; advances in molecular genetics have uncovered hereditary and germline mutations of at least 10 genes that contribute to the development of these tumors, and increasing knowledge of genotype-phenotype interactions has facilitated more accurate determination of malignant potential. Elucidating the molecular mechanisms responsible for malignant transformation in these tumors has opened avenues of investigation into targeted therapeutics that show promising results. There have also been significant advances in functional and radiological imaging and in the surgical approach to adrenalectomy, which remains the mainstay of treatment for PCC. In this review, we discuss the currently available diagnostic and therapeutic options for patients with malignant PCCs and PGLs and detail the molecular rationale and clinical evidence for novel and emerging diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.